drugset / Trial / NCT03969420
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2021-04-22
- Completion
- 2021-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Subcutaneous |
| Subject | alvocidib | Small molecule | — | Intravenous |